Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELICIT real-world pharmacokinetics of immune checkpoint inhibitors
NL-OMON51955Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2021
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by Radboud University Medical Center. Primary endpoints: Trough concentration, Peak concentration and 2 more. Started Sep 2021; status: completed.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON51955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51955.